Classes
DEA Class; Rx
Common Brand Names; Viekira Pak (DSC)
- HCV NS5A Inhibitors;
- HCV Polymerase Inhibitors;
- HCV Protease Inhibitors
Description
Combination oral product containing 3 antivirals with activity against HCV and a pharmacokinetic enhancer
For HCV genotype 1a and 1b, including patients with and without compensated cirrhosis
Contraindicated in patients with moderate to severe hepatic disease (Child-Pugh Class B and C)
Indications
Indicated for the treatment of chronic hepatitis C infection.
Warnings
—
Maximum Dosage
500 mg/day PO for dasabuvir; 25 mg/day PO for ombitasvir; 150 mg/day PO for paritaprevir; 100 mg/day PO for ritonavir.
500 mg/day PO for dasabuvir; 25 mg/day PO for ombitasvir; 150 mg/day PO for paritaprevir; 100 mg/day PO for ritonavir.
Safety and efficacy not established.
Safety and efficacy not established.
Safety and efficacy not established.
Safety and efficacy not established.
How supplied
ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) (Discontinued)
Fixed-dose combination discontinued in 2015 owing to hepatoxicity